Hif1a Cancer Research Results

Hif1a, HIF1α/HIF1a: Click to Expand ⟱

Source:

Type:

Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.

Scientific Papers found: Click to Expand⟱

8235-

LCA,

Anticancer effects of licochalcones: A review of the mechanisms

-

Review,

Var,

NA

mt-Apoptosis↑, TumAuto↑, TumCMig↓, LC3‑Ⅱ/LC3‑Ⅰ↑, ATG5↑, ATG7↑, p62↑, CHOP/DDIT3↑, ER Stress↑, UPR↑, ATG3↑, Beclin-1/ATG6↑, ATG16L1↑, PERK↑, ATF4↑, ATP↓, Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, Bcl-xL↓, Bcl-2↓, BAD↑, BAX↑, Casp3↑, survivin↓, EGFR↓, ERK↓, Akt↓, mtDam↑, MMP↓, Cyt‑c↑, Casp↑, MDM2↓, CycB/CCNB1↓, CDC2↓, CDC25↓, TumCCA↑, TumCP↓, Wnt↓, β-catenin/ZEB1↓, Sp1/3/4↓, MMP-10↓, MMP3↓, TumCI↓, Imm↑, PD-L1↓, ROS↑, 4E-BP1↓, eIF2α↓, PI3K↓, mTOR↓, p‑cMET↑, Ca+2↑, RUBCN↓, ATG13↑, TSC1↑, TSC2↑, PRAS40↑, PP2A↑, ULK1/ATG1↑, THEM4/CTMP↑, DR5↑, Fas↑, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, PKCδ↓, P70S6K↓, VEGF↓, angioG↓, HK2↓, Glycolysis↓, TrxR1↓, APAF1↑, cl‑PARP↑, Bax:Bcl2↑, ABCG2↓, BioEnh↑,

8213-

LCA,

Licochalcone A inhibits hypoxia-inducible factor-1α accumulation by suppressing mitochondrial respiration in hypoxic cancer cells

-

in-vitro,

CRC,

HCT116

-

in-vitro,

Lung,

H1299

-

in-vitro,

Lung,

H322

Hif1a↓, GLUT1↓, PDK1 / PDPK1↓, ROS↑, mitResp↓, ATP↓, tumCV?,

8224-

LCA,

3,3',4,4'-Tetrahydroxy-2-methoxychalcone from Glycyrrhiza uralensis roots inhibits HIF-1α and Nrf2, suppressing hypoxia-induced angiogenesis

-

in-vitro,

CRC,

HCT116

Hif1a↓, NRF2↓, VEGF↓, HO-1↓, ROS↓,

8290-

LE,

Licoricidin, an Active Compound in the Hexane/Ethanol Extract of Glycyrrhiza uralensis, Inhibits Lung Metastasis of 4T1 Murine Mammary Carcinoma Cells

-

vitro+vivo,

Pca,

DU145

mice

*toxicity↝, Apoptosis↑, TumCCA↑, TumCMig↓, CD31/PECAM-1↓, Hif1a↓, iNOS↓, COX2/PTGS2↓, VEGF↓, MMP9↓, ICAM-1↓, VCAM-1↓,

8236-

LE,

Licorice (Glycyrrhiza glabra L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects

-

Review,

Var,

NA

Bcl-2↓, CDK2↓, PI3K↓, cJun↓, mTOR↓, NF-kB↓, VEGF↓, MMP3↓, toxicity↓, Dose↑, chemoP↑, *antiOx↑, *Inflam↓, Dose↝, *COX2/PTGS2↓, *iNOS↓, *IL6↓, *IL10↓, *PGE2↓, *IκB?, *NRF2↑, *HO-1↑, *lipid-P↓, *ROS↓, *Catalase↑, *GPx↑, *SOD↑, Apoptosis↑, ROS↑, TumCP↓, TumCCA↑, cycE/CCNE↓, cycD1/CCND1↓, p‑GSK‐3β↓, PI3K↓, MKK4↓, MKK7↓, HSP90↓, LC3‑Ⅱ/LC3‑Ⅰ↑, Beclin-1/ATG6↑, p62↓, p‑Akt↓, cl‑Casp9↑, cl‑Casp7↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Cyt‑c↑, P53↑, STAT3↓, E-cadherin↑, Vim↓, N-cadherin↓, CD31/PECAM-1↓, Hif1a↓, iNOS↓, DNAdam↑, MMP↓, BIM↑, APAF1↑, PCNA↓, toxicity↝, eff↑,

8281-

LE,

A Licorice Roots Extract Induces Apoptosis and Cell Cycle Arrest and Improves Metabolism via Regulating MiRNAs in Liver Cancer Cells

-

in-vitro,

Liver,

NA

Apoptosis↑, TumCCA↑, Let-7↑, miR-34b-5p↑, miR-122-5p↑, miR-126↑, miR-195↑, miR-199↑, miR-206↑, miR-326-5p↑, Hif1a↓, PI3K↓, cMyc↓, AMPK↑, P53↑, Glycolysis↓, HK2↓, LDHA↓, PKM2↓, PPP↓, G6PD↓, GlutaM↓, GLS↓, miR-21↑, miR-221↑, miR-222↑,

8401-

LT,

Multi-Faceted Role of Luteolin in Cancer Metastasis: EMT, Angiogenesis, ECM Degradation and Apoptosis

-

Review,

Var,

NA

EMT↓, N-cadherin↓, Vim↓, VEGF↓, VEGFR1↓, MMPs↓, Telomerase↓, NF-kB↓, cMyc↓, Bax:Bcl2↑, Casp3↑, PI3K↓, Akt↓, FOXO3↑, P21↑, p27/CDKN1B↑, cl‑PARP↑, Cyt‑c↑, NOTCH↓, HES1↓, ROS↑, SOD↓, miR-34b-5p↑, Hif1a↓, P21↓, survivin↓, Mcl-1?, Bcl-xL↓, MDM2↓, MMP2↓, MMP9↓, MMP3↓, MMP16↓, miR-384↑, NRF2↓, HO-1↓, angioG↓,

2906-

LT,

Luteolin, a flavonoid with potentials for cancer prevention and therapy

-

Review,

Var,

NA

*Inflam↓, AntiCan↑, antiOx⇅, Apoptosis↑, TumCP↓, TumMeta↓, angioG↓, PI3K↓, Akt↓, NF-kB↓, XIAP↓, P53↑, *ROS↓, *GSTA1↑, *GSR↑, *SOD↑, *Catalase↑, *other↓, ROS↑, Dose↝, chemoP↑, NF-kB↓, JNK↑, p27/CDKN1B↑, P21↑, DR5↑, Casp↑, Fas↑, BAX↑, MAPK↓, CDK2↓, IGF-1↓, PDGF↓, EGFR↓, PKCδ↓, TOP1↓, TOP2↓, Bcl-xL↓, FASN↓, VEGF↓, VEGFR2/KDR/Flk1↓, MMP9↓, Hif1a↓, FAK↓, MMP1↓, Twist↓, ERK↓, P450↓, CYP1A1↓, CYP1A2↓, TumCCA↑,

2912-

LT,

Luteolin: a flavonoid with a multifaceted anticancer potential

-

Review,

Var,

NA

ROS↑, TumCCA↑, TumCP↓, angioG↓, ER Stress↑, mtDam↑, PERK↑, ATF4↑, eIF2α↑, cl‑Casp12↑, EMT↓, E-cadherin↑, N-cadherin↓, Vim↓, *neuroP↑, NF-kB↓, PI3K↓, Akt↑, XIAP↓, MMP↓, Ca+2↑, BAX↑, Casp3↑, Casp9↑, Bcl-2↓, Cyt‑c↑, IronCh↑, SOD↓, *ROS↓, *LDHA↑, *SOD↑, *GSH↑, *BioAv↓, Telomerase↓, cMyc↓, hTERT/TERT↓, DR5↑, Fas↑, FADD↑, BAD↑, BOK↑, BID↑, NAIP↓, Mcl-1↓, CDK2↓, CDK4↓, MAPK↓, AKT1↓, Akt2↓, *Beclin-1/ATG6↓, Hif1a↓, LC3II↑, Beclin-1/ATG6↑,

8348-

Lut,

Lutein inhibits proliferation, invasion and migration of hypoxic breast cancer cells via downregulation of HES1

-

in-vitro,

BC,

MCF7

-

in-vitro,

BC,

MDA‑MB‑157

TumCP↓, Apoptosis↑, Hif1a↓, NOTCH↓, HES1↓, EMT↓, TumCI↓, TumCMig↓, ROS↓,

8343-

Lut,

Association of Lutein with Cancer: A Systematic Review of the Lutein Effects on Cellular Processes Involved in Cancer Progression

-

Review,

Var,

NA

*antiOx↑, *Inflam↓, Risk↓, AntiCan∅, Apoptosis↑, ROS↓, NRF2↓, Akt↓, ERK↓, NF-kB↓, Bcl-2↓, BAX↑, Casp3↑, DNAdam↑, ROS↓, P53↑, PCNA↓, cycD1/CCND1↓, TumCP↓, Hif1a↓, NOTCH↓, miR-590-3p↑, TumCMig↓, TumCI↓, TumMeta↓, TumCA↓, *BioAv↓,

3276-

Lyco,

Lycopene modulates cellular proliferation, glycolysis and hepatic ultrastructure during hepatocellular carcinoma

-

in-vivo,

HCC,

NA

Female BALB/c mice

G6PD↓, PCNA↓, cycD1/CCND1↓, P21↑, Hif1a↓, Glycolysis↓,

1708-

Lyco,

The Anti-Cancer Activity of Lycopene: A Systematic Review of Human and Animal Studies

-

Review,

Var,

NA

OS↑, ChemoSen↑, QoL↑, PSA∅, Synergy↑, AntiCan↑, AntiCan↑, angioG↓, VEGF↓, Hif1a↓, SOD↑, Catalase↑, GPx↑, GSH↑, GPx↑, GR↑, MDA↓, NRF2↑, HO-1↑, COX2/PTGS2↓, PGE2↓, NF-kB↓, IL4↑, IL10↑, IL6↓, TNF-α↓, PPARγ↑, TumCCA↑, FOXO3↓, Casp3↑, IGF-1↓, p27/CDKN1B↑, STAT3↓, CDK2↓, CDK4↓, P21↑, PCNA↓, MMP7↓, MMP9↓,

4519-

MAG,

Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer

-

Review,

Var,

NA

*antiOx↑, *Inflam↓, *Bacteria↓, *AntiAg↑, *BBB↑, *BioAv↓, BAD↑, Casp3↑, Casp6↑, Casp9↑, JNK↑, Bcl-xL↓, PTEN↑, Akt↓, NF-kB↓, MMP7↓, MMP9↓, uPA↓, Hif1a↓, VEGF↓, FOXO3↓, Ca+2↑, TumCCA↑, ROS↑, Cyt‑c↑,

5252-

MAG,

Insights on the Multifunctional Activities of Magnolol

-

Review,

Var,

NA

BioAv↓, *Inflam↓, *Bacteria↓, *antiOx↑, *neuroP↑, *cardioP↑, CYP1A1↓, *PPARγ↑, *NF-kB↓, *COX2/PTGS2↓, *iNOS↓, *ROS↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, cycA1/CCNA1↓, CDK2↓, P21↑, TumCG↓, TumCMig↓, TumCI↓, Ki-67↓, PCNA↓, MMP2↓, MMP9↓, MMP7↓, DNAdam↑, MMP↓, TumCP↓, selectivity↑, PI3K↓, Akt↓, H2O2↓, Hif1a↓, *BDNF↑, *NRF2↑, *AChE↑,

972-

MAG,

Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells

-

vitro+vivo,

Bladder,

T24/HTB-9

angioG↓, VEGF↓, H2O2↓, Hif1a↓, VEGFR2/KDR/Flk1↓, Akt↓, mTOR↓, P70S6K↓, 4E-BP1↓, TumCG↓, CD31/PECAM-1↓, CA↓,

8633-

MBZ,

Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells

-

in-vitro,

BC,

MDA-MB-231

-

in-vitro,

BC,

MCF7

Hif1a↓, HIF2a↓, ARNT?,

2500-

MBZ,

Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme

-

in-vitro,

GBM,

U87MG

 0.1 to 0.3 µM

-

in-vivo,

GBM,

NA

Female C57BL/6 mice

α-tubulin↓, AntiCan↑, TumCG↓, OS↑, VEGF↓, Hif1a↓,

2487-

mCHEMO,

Metronomic Chemotherapy: Possible Clinical Application in Advanced Hepatocellular Carcinoma

-

Review,

HCC,

NA

toxicity↓, toxicity↓, eff↝, angioG↓, CSCs↓, TSP-1↑, Hif1a↓, VEGF↓, eff↑,

8783-

mCHEMO,

Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancers

-

in-vitro,

Colon,

HT-29

compared the effect of MTD or LDM chemotherapy upon HIFα in models of advanced, metastatic colon and breast cancer.

-

in-vitro,

BC,

NA

ChemoSideEff↓, Hif1a↓,

8786-

mCHEMO,

Metronomic chemotherapy in cancer treatment: new wine in an old bottle

-

Review,

Var,

NA

eff↑, ChemoSideEff↓, angioG↓, *toxicity↓, PFS↑, Hif1a↓, TumCD↑, CSCs↓, EMT↓, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, CD133↓, TumCCA↑, P21↓, DNAdam↑, Imm↑, Synergy↑, Synergy↑,

8819-

MCP,

PacT,

Pectasol‐C Modified Citrus Pectin targets Galectin‐3‐induced STAT3 activation and synergize paclitaxel cytotoxic effect on ovarian cancer spheroids

-

in-vitro,

Ovarian,

SKOV3

Gal-3↓, ChemoSen↑, STAT3↓, Hif1a↓, Akt↓, TumCMig↓, TumCI↓, ITGA2↓, ITGA5↓, ITGA6↓, ITGB1↓, ITGB3↓, ITGB4↓,

8816-

MCP,

Modified citrus pectin inhibits breast cancer development in mice by targeting tumor-associated macrophage survival and polarization in hypoxic microenvironment

-

vitro+vivo,

BC,

MDA-MB-231

Balb/c mice (female, 5-week-old)

-

in-vitro,

BC,

4T1

GlucoseCon↓, GLUT1↓, Gal-3↓, ROS↓, NRF2↓, Hif1a↓, angioG↓, pol-M2 MC↓, p‑STAT3↓, TumCG↓, TumW↓,

8756-

MeSA,

THE MAIN CYTOTOXIC EFFECTS OF METHYLSELENINIC ACID ON VARIOUS CANCER CELLS

-

Review,

Var,

NA

ROS↑, GSH↓, RadioS↑, angioG↓, p‑Akt↓, IκB↓, NF-kB↓, ITGB3↓, p‑FOXO3↓, BAX↑, Cyt‑c↑, proCasp3↑, PARP↑, Glycolysis↓, TCA↓, NRF2↑, DNMT1↓, Hif1a↓, ER Stress↑, ChemoSen↑,

8748-

MeSA,

Methylseleninic acid elevates REDD1 and inhibits prostate cancer cell growth despite AKT activation and mTOR dysregulation in hypoxia

-

in-vitro,

Pca,

LNCaP

-

in-vitro,

Pca,

PC3

Hif1a↓, DDIT4?, p‑Akt↑, P70S6K↑, TumCG↓,

8762-

MeSA,

Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels

-

in-vitro,

Ovarian,

A2780S

selectivity↑, NK cell↑, T-Cell↑, PD-L1↓, Hif1a↓, VEGF↓, ROS↑, *NRF2↑,

2378-

MET,

Metformin inhibits epithelial-mesenchymal transition of oral squamous cell carcinoma via the mTOR/HIF-1α/PKM2/STAT3 pathway

-

in-vitro,

SCC,

CAL27

0, 2.5, 5, 10, 20, 40, 80 and 160 mM) for 24 h

-

in-vivo,

NA,

NA

Xenograft mouse

TumCP↓, TumCMig↓, TumCI↓, EMT↓, mTOR↓, Hif1a↓, PKM2↓, STAT3↓, E-cadherin↑, Vim↓, Snail↓, STAT3↓,

2376-

MET,

Metformin Inhibits Epithelial-to-Mesenchymal Transition of Keloid Fibroblasts via the HIF-1α/PKM2 Signaling Pathway

-

in-vitro,

Nor,

NA

10, 15, 20 mM

*Hif1a↓, *EMT↓, *p‑P70S6K↓, *PKM2↓,

2375-

MET,

Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling

-

in-vitro,

GC,

SGC-7901

0-50mM

tumCV↓, TumCI↓, TumCMig↓, Apoptosis↑, PARP↓, PI3K↓, Akt↓, Hif1a↓, PKM2↓, COX2/PTGS2↓,

2386-

MET,

Mechanisms of metformin inhibiting cancer invasion and migration

-

Review,

Var,

NA

OS↑, AMPK↑, EMT↓, TGF-β↓, mTOR↓, P70S6K↓, PKM2↓, Hif1a↓, ChemoSen↑,

2371-

MET,

The role of pyruvate kinase M2 in anticancer therapeutic treatments

-

Review,

Var,

NA

ChemoSen↑, PKM2↓, Hif1a↓, EMT↓,

970-

MET,

Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer

-

in-vitro,

BC,

NA

CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,

1066-

MET,

Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma

-

in-vitro,

SCC,

NA

PDH↑, Hif1a↓, TumCMig↓, Casp3↑, P53∅,

2245-

MF,

Quantum based effects of therapeutic nuclear magnetic resonance persistently reduce glycolysis

-

in-vitro,

Nor,

NIH-3T3

Warburg↓, Hif1a↓, *Hif1a∅, Glycolysis↓, *lactateProd↓, *ADP:ATP↓, Pyruv↓, ADP:ATP↓, *PPP↓, *mt-ROS↑, *ROS↓, RPM↑, *ECAR↓,

4110-

MF,

Pulsed Electromagnetic Fields: A Novel Attractive Therapeutic Opportunity for Neuroprotection After Acute Cerebral Ischemia

-

Review,

Stroke,

NA

*ROS↓, *Inflam↓, *other↝, *neuroP↑, *Apoptosis↓, *Hif1a↝,

3476-

MF,

Pulsed Electromagnetic Fields Stimulate HIF-1α-Independent VEGF Release in 1321N1 Human Astrocytes Protecting Neuron-like SH-SY5Y Cells from Oxygen-Glucose Deprivation

-

in-vitro,

Stroke,

1321N1

1.5 ± 0.2 mT, pulse duration of 1.3 ms and frequency of 75 Hz, yielding a 0.1 duty cycle

-

in-vitro,

Park,

NA

*VEGF↑, *eff↑, *neuroP↑, *other↑, *eff↑, *Inflam↓, *Hif1a∅,

3479-

MF,

Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies

-

Review,

Var,

NA

*eff↓, eff↝, *Hif1a↑, *VEGF↑, *TIMP1↑, *E2Fs↑, *MMP2↑, *MMP9↑, Apoptosis↑,

3482-

MF,

Pulsed Electromagnetic Fields Increase Angiogenesis and Improve Cardiac Function After Myocardial Ischemia in Mice

-

in-vitro,

Nor,

NA

mice

*cardioP↑, *VEGF↑, *VEGFR2/KDR/Flk1↑, *Hif1a↑, *FGF↑, *ITGB1↑, *angioG↑,

8740-

MGO,

Methylglyoxal induces ambience for cancer promotion in HepG2 cells via Warburg effect and promotes glycation

-

in-vitro,

Liver,

HepG2

GLO-I↓, HAGH/GLO2↓, RAGE↑, AGEs↑, Hypoxia↑, ROS↑, GlucoseCon↑, GLUT1↑, HK2↑, PFK1↑, LDH↑, lactateProd↑, Glycolysis↑, Hif1a↑, Warburg↑,

8670-

MLT,

Antitumor Effects of Melatonin in Luminal and Triple-Negative Breast Cancer Cells: Metabolic Reprogramming, Redox Regulation, and Cellular Dynamics

-

in-vitro,

BC,

MCF7

-

in-vitro,

BC,

MDA-MB-231

tumCV↓, TumCMig↓, TumCI↓, GAPDH↓, Hif1a↓, citrate↓, ROS↑, lipid-P↑, LDH↓, G6PD↓, MDA?, Catalase↓, GPx↑, GSH↑, *ROS↓,

8663-

MLT,

Melatonin suppresses Akt/mTOR/S6K activity, induces cell apoptosis, and synergistically inhibits cell growth with sunitinib in renal carcinoma cells via reversing Warburg effect

-

vitro+vivo,

RCC,

786-O

TumCG↓, ROS↑, TAC↓, TCA↑, Glycolysis↓, OCR↑, ATP↑, MMP↑, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Hif1a↓, VEGFR1↓, eff↓, Synergy↑, Warburg↓, TumCP↓, SOD↓, GSH↓, Catalase↓, GPx↑, Warburg↓, OXPHOS↑, Hif1a↓, VEGF↓, Ki-67↓, Akt↓, mTOR↓,

8691-

MLT,

Melatonin effect on hypoxia inducible factor-1α and clinical response in patients with oral squamous cell carcinoma receiving neoadjuvant chemotherapy: A randomized controlled trial

-

Trial,

Oral,

NA

Hif1a↓, Dose?, eff∅,

8687-

MLT,

Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma

-

in-vitro,

CRC,

T24/HTB-9

-

in-vitro,

Bladder,

UMUC3

TumCP↓, TumCCA↑, Hif1a↓, NF-kB↓, Bcl-2↓, ROS↑, Akt↓, PCNA↓, cycD1/CCND1↓, BAX↓, Apoptosis?, ChemoSen↑, Wnt↓, β-catenin/ZEB1↓, COX2/PTGS2↓, PGE2↓, NF-kB↓, PI3K↓, Akt↓, P53↑, P21↑, *cardioP?, *NRF2↑, *HO-1↑, *RenoP↑, chemoP↑,

8673-

MLT,

Therapeutic Potential of Melatonin in Gastrointestinal Cancers: Molecular Mechanisms, Preclinical Evidence and Clinical Implications

-

Review,

GC,

NA

ChemoSen↑, TumVol↓, β-catenin/ZEB1↓, Risk↓, radioP↑, Mucositis↓, Dose↝, toxicity↓, BioAv↓, *antiOx↑, *SOD↑, *GPx↑, *Catalase↑, *NRF2↑, Apoptosis↑, Estro↝, Telomerase↓, *ROS↓, angioG↓, Imm↑, TumCCA↑, Glycolysis↓, OXPHOS↑, mTORC1↓, VEGF↓, Hif1a↓, ROS↓, TumAuto↓, HSP70/HSPA5↓, PI3K↓, Akt↓, mTOR↓, BAX↑, Casp↑, Cyt‑c↑, tumCV↓, TumCMig↓, TumCI↓, TumVol↓, TumW↓, P21↑, P53↑, Synergy↑, ER Stress↑, Synergy↑, RadioS↑, eff↑, eff↑, fatigue↓, Sleep↑,

8680-

MLT,

Function of intramitochondrial melatonin and its association with Warburg metabolism

-

Analysis,

Var,

NA

mt-ROS↓, Glycolysis↓, TumCP↓, SIRT3↑, FOXO↑, PDH↑, Hif1a↓, PDK1 / PDPK1↓, Warburg↓,

1782-

MLT,

Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities

-

Review,

Var,

NA

AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, Synergy↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,

971-

MLT,

Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells

-

in-vitro,

Pca,

DU145

-

in-vitro,

Pca,

PC3

-

in-vitro,

Pca,

LNCaP

Hif1a↓, VEGF↓, p‑p70S6↓,

1203-

MSM,

Methylsulfonylmethane Suppresses Breast Cancer Growth by Down-Regulating STAT3 and STAT5b Pathways

-

vitro+vivo,

BC,

MDA-MB-231

tumCV↓, STAT3↓, STAT5↓, IGF-1↓, Hif1a↓, VEGF↓, Brk/PTK6↓, IGF-1R↓,

8809-

MT/VAE,

Cisplatin,

Synergistic Effects of Mistletoe Lectin and Cisplatin on Triple-Negative Breast Cancer Cells: Insights from 2D and 3D In Vitro Models

-

in-vitro,

BC,

MDA-MB-231

TumCP↓, Apoptosis↑, TumCCA↑, VEGF↓, Hif1a↓,

8961-

mushLions,

A Novel Erinacine S Derivative from Hericium erinaceus Overcomes Chemoresistance in Colorectal Cancer Cells by Enhancing TRAIL/TNFR1/DR5 Expression through Histone Acetylation

-

in-vivo,

CRC,

NA

in vivo xenograft mouse model

Apoptosis↑, TRAIL↑, TNFR 1↑, DR5↑, p‑Akt↓, p‑ERK↓, Hif1a↓, PCNA↓, NF-kB↓, TumCI↓, TumCMig↓, TumCP↓,

Showing Research Papers: 201 to 250 of 359
Prev Page 5 of 8 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 359

Pathway results for Effect on Cancer / Diseased Cells:

NA, unassigned(tgid=0) ⓘ

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 4, antiOx↑, 7, antiOx⇅, 1, Catalase↓, 4, Catalase↑, 3, Fenton↑, 3, frataxin↑, 1, GPx↓, 1, GPx↑, 4, GPx4↓, 3, GPx4↑, 1, GSH↓, 12, GSH↑, 5, GSH/GSSG↓, 1, GSTs↑, 2, H2O2↓, 3, H2O2↑, 4, HO-1↓, 7, HO-1↑, 9, HO-2↓, 1, Iron↑, 3, Iron∅, 1, lipid-P↓, 3, lipid-P↑, 8, MDA?, 1, MDA↓, 1, MDA↑, 3, MPO↓, 3, NADH↓, 1, NADPH/NADP+↓, 1, NOX4↑, 1, NQO1?, 1, NQO1↑, 1, Nrf1↑, 1, NRF2↓, 16, NRF2↑, 21, p‑NRF2↓, 1, p‑NRF2↑, 1, Prx↓, 1, PrxI↓, 1, RNS↑, 1, ROS?, 1, ROS↓, 19, ROS↑, 127, ROS⇅, 4, ROS↝, 1, ROS∅, 1, i-ROS↑, 1, mt-ROS↓, 1, mt-ROS↑, 2, RPM↑, 1, SOD↓, 5, SOD↑, 5, SOD2↓, 2, SOD2↑, 1, TAC↓, 1, TKT↝, 1, Trx↓, 1, ox-Trx1↑, 1, TrxR↓, 5, TrxR1↓, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1, IronCh↑, 1, NCOA4↑, 1, Tf↓, 1, Tf↑, 1,

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1, BCR-ABL↓, 1, CDC2↓, 1, CDC25↓, 2, compI↓, 1, EGF↓, 1, ETC↓, 3, ETC↝, 1, MCU↓, 1, mitResp↓, 4, MKK7↓, 1, Mortalin↓, 1, mtDam↑, 8, OCR↓, 6, OCR↑, 4, OXPHOS↓, 1, OXPHOS↑, 7, mt-OXPHOS↓, 2, PDH↓, 3, PDH↑, 5, PDH↝, 1, PGC-1α↑, 1, SDH↓, 1, SIRT3↓, 2, SIRT3↑, 6,

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1, 5LO↓, 1, AApath↓, 1, ACC↓, 2, ACLY↓, 1, Alanine↓, 1, ALAT↓, 1, ALAT↝, 1, ALDOA↓, 1, AMACR↓, 1, AMP↓, 1, AMPK↑, 18, p‑AMPK↑, 3, p‑AMT/GCST/T-protein↑, 1, ATP↓, 21, ATP↑, 2, ATP↝, 1, i-ATP↓, 1, CAIX/CA9↓, 2, CAIX/CA9↑, 1, citrate↓, 2, i-citrate↑, 1, CPT1A↓, 1, ECAR↓, 8, ECAR↝, 1, ENO1↓, 2, FASN↓, 7, FASN↑, 1, FDG↓, 1, G6PD↓, 5, GAPDH↓, 1, GLO-I↓, 1, GLS↓, 3, glucoNG↓, 1, GlucoseCon↓, 24, GlucoseCon↑, 3, glut↓, 1, GlutaM↓, 1, GlutMet↓, 2, Glycine↓, 1, Glycolysis↓, 75, Glycolysis↑, 3, GPI↓, 1, GSK‐3β↓, 5, GSK‐3β↑, 1, p‑GSK‐3β↓, 5, HAGH/GLO2↓, 1, HK1↓, 1, HK2↓, 34, HK2↑, 2, HMG-CoA↓, 2, IDH1↑, 1, lact/pyru↓, 1, lactateProd↓, 22, lactateProd↑, 4, e-lactateProd↓, 1, LAR↓, 1, LDHA↓, 26, LDHA↑, 1, LDL↓, 1, lipoGen↓, 1, MCT4↓, 1, NADPH↓, 4, NADPH↑, 1, PDK1 / PDPK1?, 2, PDK1 / PDPK1↓, 19, p‑PDK1 / PDPK1↓, 1, PDK3↓, 1, PDKs↓, 2, PFK↓, 5, PFK1↓, 3, PFK1↑, 1, PFK2?, 1, PFKP?, 1, PFKP↓, 1, PKM2↓, 39, PKM2:PKM1↓, 1, PPP↓, 1, Pyruv↓, 2, R5P↝, 1, p‑S6↓, 2, SCD1↓, 2, SHARP↑, 1, SIRT1↓, 4, SIRT1↑, 8, SIRT2↓, 1, SIRT2↑, 1, SREBP1/SREBF1↓, 1, SREBP2↓, 2, TCA↓, 3, TCA↑, 1, TPI↓, 1, Warburg↓, 14, Warburg↑, 1, β-oxidation↓, 1,

Cell Death(tgid=5) ⓘ

AIF↑, 4, APAF1↑, 5, Apoptosis?, 1, Apoptosis↓, 5, Apoptosis↑, 101, mt-Apoptosis↑, 1, ASK1↑, 1, aSmase↝, 1, BAD↓, 1, BAD↑, 5, Bak↑, 5, BAX↓, 2, BAX↑, 51, BAX⇅, 1, Bax:Bcl2↓, 1, Bax:Bcl2↑, 12, Bcl-2↓, 56, Bcl-2↑, 2, Bcl-xL↓, 20, BID↓, 1, BID↑, 2, BIM↓, 1, BIM↑, 2, BNIP3↑, 1, BNIP3↝, 1, BOK↑, 1, Casp↑, 13, Casp↝, 1, Casp∅, 1, cl‑Casp↑, 1, Casp1↑, 1, Casp12?, 1, Casp12↑, 2, cl‑Casp12↑, 1, Casp2↑, 1, Casp3↓, 1, Casp3↑, 80, cl‑Casp3↑, 8, proCasp3↑, 2, Casp6↑, 1, Casp7↑, 8, cl‑Casp7↑, 3, Casp8↑, 8, cl‑Casp8↑, 3, pro‑Casp8↑, 1, Casp9↑, 45, cl‑Casp9↑, 5, cFLIP↓, 5, CSR1↑, 1, Cyt‑c↓, 1, Cyt‑c↑, 44, Diablo↑, 5, DR5↑, 12, FADD↑, 3, Fas↓, 1, Fas↑, 11, FasL↑, 3, Ferroptosis↓, 1, Ferroptosis↑, 10, GSDME↑, 1, HEY1↓, 1, IAP1↓, 1, IAP2/BIRC3↓, 1, cl‑IAP2/BIRC3↑, 1, iNOS↓, 12, JWA↑, 1, Mcl-1?, 1, Mcl-1↓, 18, Mcl-1↑, 1, MDM2↓, 3, MDM2↑, 1, MOMP↑, 1, NAIP↓, 1, Necroptosis↑, 1, necrosis↑, 2, NOXA↑, 1, oncosis↑, 1, p38↓, 3, p38↑, 4, p‑p38↓, 1, PUMA↑, 3, Pyro↑, 1, RIP1↑, 1, RIP3↑, 1, survivin↓, 25, TNFR 1↑, 1, TRAIL↑, 3, TumCD↑, 5, TUNEL↑, 1, XIAP↓, 14, XIAP↝, 1, YAP/TEAD↓, 2,

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 82, Akt↑, 7, Akt↝, 1, Akt∅, 1, p‑Akt↓, 30, p‑Akt↑, 2, AKT1↓, 2, Akt2↓, 1, AMPKα↑, 2, Brk/PTK6↓, 1, CaMKII ↓, 1, CIP2A↓, 1, CK2↓, 5, cMET↓, 2, p‑cMET↑, 1, DDIT4?, 1, EF-1α↓, 1, EGFR↓, 29, EphB4↓, 2, ERK↓, 29, ERK↑, 2, ERK↝, 1, ERK∅, 1, p‑ERK↓, 10, p‑ERK↑, 1, FLT4↓, 1, FOXD3↑, 1, HER2/EBBR2↓, 7, HGF/c-Met↓, 1, HRAS↓, 1, IGF-1R↓, 5, IKKα↓, 5, p‑IKKα↓, 1, ILK↓, 1, IκB↓, 1, JAK↓, 3, p‑JAK1↓, 1, JAK2↓, 4, p‑JAK2↓, 1, JNK↓, 2, JNK↑, 12, p‑JNK↓, 2, MAPK↓, 19, MAPK↑, 3, MAPK↝, 1, MARK4↓, 1, MEK↓, 4, MKK4↓, 1, mTOR↓, 50, p‑mTOR↓, 11, p70S6↓, 2, p‑p70S6↓, 2, P70S6K↓, 3, P70S6K↑, 1, p‑P70S6K↓, 3, P90RSK↓, 1, p‑P90RSK↑, 1, PAK↓, 1, PDGFRB↓, 1, PFKFB2↓, 1, PI3K↓, 65, PI3K↑, 3, PI3K↝, 1, p‑PI3K↓, 1, p‑PI3K↑, 1, PI3K/Akt↓, 3, PI3k/Akt/mTOR↓, 2, p‑PI3k/Akt/mTOR↓, 1, PIK3CA↓, 1, PKA↓, 1, PKCδ↓, 9, PKCδ↑, 1, PP2A↑, 1, PRAS40↑, 1, PTEN↓, 1, PTEN↑, 22, Raf↓, 3, c-Raf↓, 1, RAS↓, 1, p‑S6K↓, 2, Sp1/3/4↓, 8, Src↓, 1, STAT↓, 2, STAT3↓, 55, p‑STAT3↓, 6, p‑STAT3↑, 1, STAT5↓, 1, THEM4/CTMP↑, 1, TSC2↑, 1,

Transcription & Epigenetics(tgid=7) ⓘ

ARNT?, 1, ATF3↑, 1, ATF4↑, 3, cJun↓, 1, cJun↑, 1, cMyc↓, 27, DNMT1↓, 5, DNMT3A↓, 1, DNMTs↓, 7, EZH2↓, 3, FOXM1↓, 2, FOXO↑, 2, FOXO3↓, 3, FOXO3↑, 3, p‑FOXO3↓, 1, FOXO4↓, 1, H3↓, 1, H3↑, 1, ac‑H3↑, 3, H4↑, 1, ac‑H4↑, 2, HATs↓, 2, HATs↑, 3, HDAC↓, 22, HDAC1↓, 2, HDAC10↓, 1, HDAC2↓, 3, HDAC3↓, 2, HDAC4↓, 2, HDAC8↓, 1, HES1↓, 2, miR-122-5p↑, 1, miR-124-3p↓, 1, miR-126↑, 1, miR-155↓, 2, miR-195↑, 1, miR-199↑, 1, miR-203↓, 1, miR-203↑, 1, miR-206↑, 1, miR-21↓, 3, miR-21↑, 1, miR-210↓, 1, miR-210↑, 1, miR-221↑, 1, miR-222↑, 1, miR-27a-3p↓, 1, miR-29b↓, 1, miR-30a-5p↑, 1, miR-326-5p↑, 1, miR-339-5p↝, 1, miR-34a↑, 1, miR-34b-5p↑, 2, miR-375↑, 1, miR-384↑, 1, miR-590-3p↑, 1, Myc↓, 4, n-MYC↓, 1, OCT4↓, 4, other↓, 2, other↑, 1, other↝, 6, SOX2↓, 4, SOX4↓, 1, SOX9?, 1, SPP1↓, 1, SUV39H↓, 3, TFAP2A↓, 1, tumCV?, 1, tumCV↓, 17, ZBTB10↑, 1,

Protein Folding & ER Stress(tgid=8) ⓘ

ATF6↑, 1, CHOP/DDIT3↑, 11, cl‑CHOP/DDIT3↑, 1, eIF2α↓, 2, eIF2α↑, 1, p‑eIF2α↑, 2, ER Stress↑, 22, GRP78/BiP↓, 1, GRP78/BiP↑, 8, Hsc70↓, 1, HSP70/HSPA5↓, 3, HSP70/HSPA5↑, 1, HSP90↓, 15, HSP90↑, 1, HSPs↓, 1, IRE1↑, 1, PERK↑, 4, UPR↑, 5, XBP-1↓, 1,

Autophagy & Lysosomes(tgid=9) ⓘ

ATG13↑, 1, ATG16L1↑, 1, ATG3↑, 1, ATG5↑, 2, ATG5↝, 1, ATG7↑, 2, Beclin-1/ATG6↓, 3, Beclin-1/ATG6↑, 6, Beclin-1/ATG6↝, 1, LAMP2↑, 1, LC3‑Ⅱ/LC3‑Ⅰ↑, 3, LC3B-II↑, 1, LC3II↓, 1, LC3II↑, 6, LC3s↑, 1, p62↓, 4, p62↑, 2, RUBCN↓, 1, TumAuto↓, 1, TumAuto↑, 21, TumAuto↝, 1, ULK1/ATG1↑, 1,

DNA Damage & Repair(tgid=10) ⓘ

ATM↓, 1, p‑ATM↑, 1, p‑ATR↑, 1, BRCA1↓, 1, BRCA1↝, 1, DFF45↓, 1, DNA-PK↓, 1, DNAdam↓, 3, DNAdam↑, 29, DNArepair↓, 3, DNArepair↑, 1, ERCC1↓, 1, ERCC4/XPF↓, 1, m-FAM72A↓, 1, HR↓, 1, hTERT/TERT↓, 7, importin α/β↓, 1, Ku70/XRCC6↓, 1, MGMT↓, 1, p16↑, 3, P53?, 2, P53↓, 3, P53↑, 50, P53↝, 1, P53∅, 1, p‑P53↑, 2, p53 Wildtype↓, 1, PARP↓, 1, PARP↑, 8, PARP∅, 1, cl‑PARP↓, 2, cl‑PARP↑, 29, PARP1↓, 1, PARP1↑, 1, cl‑PARP1↑, 1, PCNA↓, 18, POLD1↓, 1, RAD51↓, 1, SIRT6↓, 1, SIRT6↑, 1, Telomerase↓, 16, TOP1↓, 5, TOP2↓, 4, TP53↑, 2, γH2AX↑, 1,

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 5, CDK1/2/5/9↓, 1, CDK2↓, 18, CDK2↑, 1, CDK4↓, 23, CDK4/6↓, 1, CDK6↓, 11, CDK6↑, 1, CDK8↓, 1, CHK1↓, 2, p‑CHK1↑, 1, Chk2↓, 1, p‑Chk2↑, 2, cycA1/CCNA1↓, 5, cycA1/CCNA1↑, 1, CycB/CCNB1↓, 11, cycD1/CCND1↓, 43, CycD3↓, 1, cycE/CCNE↓, 8, cycE/CCNE↑, 2, cycE1↓, 2, E2Fs↑, 1, Ki-67↓, 11, MAD↓, 1, mitA↑, 1, P21?, 1, P21↓, 4, P21↑, 35, p27/CDKN1B↑, 17, pRB↑, 1, p‑pRB↓, 2, RB1↑, 1, p‑RB1↓, 3, TumCCA↓, 4, TumCCA↑, 88,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

4E-BP1↓, 3, p‑4E-BP1↓, 1, ALDH↓, 3, ALDH1A1↓, 1, AXIN1↑, 1, BMPs↑, 1, CD133↓, 5, CD24↓, 2, CD34↓, 1, cFos↓, 1, cMYB↓, 2, CSCs?, 1, CSCs↓, 24, Diff↓, 1, EIF4E↓, 3, FBXW7↝, 1, FGF↓, 1, FGF↑, 1, Gli↓, 1, Gli1↓, 7, HH↓, 3, IGF-1↓, 10, IGFBP1↑, 1, IGFBP3↑, 2, Ki-67↓, 11, Let-7↑, 1, MCM2↓, 1, mTORC1↓, 8, p‑mTORC1↓, 1, Nanog↓, 4, Nestin↓, 3, NOTCH↓, 11, NOTCH1↓, 4, NOTCH1↑, 1, NOTCH1↝, 1, NOTCH3↓, 2, PTCH1↓, 1, SCF↓, 1, Shh↓, 6, Smo↓, 5, TumCG?, 1, TumCG↓, 47, TumCG↑, 2, TumCP↓, 83, TumCP↑, 3, Wnt↓, 14, Wnt/(β-catenin)↓, 8,

Migration(tgid=13) ⓘ

annexin II↓, 1, AntiAg?, 1, AntiAg↓, 1, AntiAg↑, 1, AP-1↓, 6, AP-1↝, 1, AXL↓, 1, BACH1↓, 1, CA↓, 2, Ca+2↓, 4, Ca+2↑, 16, Ca+2↝, 1, CAFs/TAFs↓, 1, CAFs/TAFs↝, 1, cal2↑, 1, CD11b↓, 1, COL4A3↓, 1, E-cadherin↓, 3, E-cadherin↑, 28, EMT?, 1, EMT↓, 50, EMT↝, 1, FAK↓, 10, p‑FAK↓, 3, Fibronectin↓, 2, GLI2↓, 2, GnT-V↝, 1, heparanase↝, 1, ITGA2↓, 1, ITGA5↓, 1, ITGA6↓, 1, ITGB1↓, 4, ITGB1↑, 1, ITGB3↓, 3, ITGB4↓, 2, ITGB6↓, 1, LAMs↓, 2, MALAT1↓, 3, MMP-10↓, 2, MMP1↓, 2, MMP13↓, 3, MMP16↓, 1, MMP2↓, 54, MMP3↓, 4, MMP7↓, 5, MMP9↓, 61, MMP9↑, 1, MMP9:TIMP1↓, 1, MMPs↓, 24, MUC4↓, 2, N-cadherin↓, 18, NCAM↑, 1, NM23↑, 1, PAK1↓, 1, PDGF↓, 6, Rho↓, 1, Rho↑, 1, ROCK1↓, 4, ROCK1↑, 1, Slug↓, 4, SMAD2↓, 2, p‑SMAD2↓, 1, SMAD3↓, 4, p‑SMAD3↓, 1, p‑SMAD4↓, 1, Snail?, 1, Snail↓, 19, talin↓, 1, TET1↑, 2, TGF-β↓, 12, TGF-β↑, 1, TIMP1↓, 1, TIMP1↑, 5, TIMP2↓, 1, TIMP2↑, 3, TSC1↑, 1, TSP-1↑, 2, TumCA↓, 1, TumCI↓, 56, TumCMig↓, 50, TumMeta↓, 39, TumMeta↑, 3, Twist↓, 10, uPA↓, 12, uPAR↓, 1, Vim?, 1, Vim↓, 24, Zeb1↓, 7, ZEB2↓, 1, α-SMA↓, 2, α-tubulin↓, 1, β-catenin/ZEB1↓, 24, β-catenin/ZEB1↑, 2,

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 86, angioG↑, 1, CD31/PECAM-1↓, 6, CD31/PECAM-1↑, 1, Endoglin↑, 1, eNOS↓, 2, HIF-1↓, 2, Hif1a↓, 314, Hif1a↑, 12, Hif1a↝, 4, HIF2a↓, 1, Hypoxia↑, 1, LOX1↓, 2, NO↓, 4, NO↑, 2, PHDs↑, 1, TYMP/ECGF1↓, 1, VCAM-1↓, 3, VEGF↓, 142, VEGF↑, 2, VEGFR1↓, 3, VEGFR2/KDR/Flk1↓, 17, VHL↓, 1,

Barriers & Transport(tgid=15) ⓘ

BBB↑, 5, CLDN1↓, 1, CLDN2↓, 1, CTR1↑, 1, EPR↑, 2, EPR↝, 1, GLUT1↓, 41, GLUT1↑, 3, GLUT2↓, 1, GLUT3↓, 3, GLUT3↑, 1, GLUT4↓, 4, MMP↓, 50, MMP↑, 2, MPT↑, 2, NHE1↓, 3, SVCT-2∅, 1, TRPM7↓, 1, ZO-1↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

ALC∅, 1, CCR7↓, 1, CD4+↓, 1, CD4+↑, 1, CD44↓, 8, CD47↓, 1, CD8+↑, 3, COX1↓, 1, COX2/PTGS2↓, 44, COX2/PTGS2↑, 3, CXCL12↓, 3, CXCL6/GCP-2↓, 1, CXCR4↓, 8, DR4↑, 3, FOXP3↓, 1, Gal-3↓, 2, HCAR1↓, 1, HMGB1↓, 3, ICAM-1↓, 1, IFN-γ↓, 2, IFN-γ↑, 3, Igs↑, 1, IL1↓, 5, IL1↑, 1, IL10↓, 5, IL10↑, 2, IL12↓, 2, IL12↑, 1, IL1α↓, 1, IL1β↓, 10, IL1β↑, 1, IL2↓, 2, IL2↑, 3, IL4↓, 1, IL4↑, 1, IL6↓, 27, IL8↓, 7, IL8↑, 1, Imm↑, 5, Imm↝, 1, INF-γ↑, 1, Inflam↓, 11, M2 MC↓, 1, pol-M2 MC↓, 1, MCP1/CCL2↓, 1, MCT1↓, 2, MDSCs↓, 1, MIP2↓, 1, mPGES-1↓, 1, NF-kB↓, 82, NF-kB↑, 2, p‑NF-kB↓, 1, NK cell↑, 5, NLRP3↓, 2, p50↓, 1, p65↓, 3, PD-1↓, 3, PD-L1↓, 7, PGE2↓, 10, PSA↓, 7, PSA∅, 1, RAGE↑, 1, T-Cell↑, 2, T-Cell↝, 1, TCF↓, 1, Th1 response↑, 3, Th2↑, 1, TLR4↓, 3, TNF-α↓, 16, TNF-α↑, 1, TNFRSF25/DR3/APO3/LARD/TRAMP/WSL1↑, 1, Treg lymp↓, 1,

Cellular Microenvironment(tgid=17) ⓘ

pH↑, 1, pH↝, 1, e-pH↑, 1, i-pH↓, 1, PLC↓, 1, TAMS↝, 1,

Synaptic & Neurotransmission(tgid=18) ⓘ

Protein Aggregation(tgid=19) ⓘ

AGEs↑, 1, Aβ↓, 1,

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↓, 1, AR↓, 8, ARNT?, 1, CYP19↓, 1, ER(estro)↓, 2, Estro↝, 1, GR↑, 1, PPARα↓, 1, PPARα↝, 1, cl‑PPARα↓, 1, PPARγ↓, 2, PPARγ↑, 5, RANKL↓, 1,

Drug Metabolism & Resistance(tgid=21) ⓘ

ABCG2↓, 1, BioAv↓, 27, BioAv↑, 21, BioAv↝, 4, BioEnh↑, 5, chemoR↓, 1, ChemoSen↑, 85, ChemoSen⇅, 1, CompStab↑, 2, CompStab↝, 1, CYP1A1↓, 4, CYP1A1↑, 1, CYP1A2↓, 1, CYP1A2↑, 1, CYP2A3/CYP2A6↓, 1, CYP2E1↑, 1, CYP3A4↓, 1, Dose?, 3, Dose↓, 4, Dose↑, 9, Dose↝, 31, Dose∅, 10, eff↓, 22, eff↑, 46, eff⇅, 1, eff↝, 12, eff∅, 1, GSTZ1↓, 1, Half-Life↓, 7, Half-Life↑, 1, Half-Life↝, 7, Half-Life∅, 1, MDR1↓, 4, P-gp/ABCB1↓, 7, P-gp/ABCB1↑, 1, P450↓, 4, RadioS↑, 34, selectivity↑, 35, Synergy↑, 65, TET2↑, 2,

Clinical Biomarkers(tgid=22) ⓘ

AFP↑, 1, ALAT↓, 1, ALAT↝, 1, ALP↓, 1, ALP↝, 1, AR↓, 8, ascitic↓, 1, AST↝, 1, BRCA1↓, 1, BRCA1↝, 1, CRP↓, 2, E6↓, 1, E7↓, 1, EGFR↓, 29, EZH2↓, 3, FOXM1↓, 2, HEC1↓, 1, HER2/EBBR2↓, 7, hTERT/TERT↓, 7, IL6↓, 27, LDH↓, 9, LDH↑, 1, Myc↓, 4, NOS2↓, 1, PD-L1↓, 7, PSA↓, 7, PSA∅, 1, RAGE↑, 1, TP53↑, 2, XIST↓, 1,

Functional Outcomes(tgid=23) ⓘ

AntiCan↓, 1, AntiCan↑, 28, AntiCan∅, 2, AntiTum↑, 7, cachexia↓, 1, cardioP↑, 6, CardioT↓, 1, chemoP↓, 1, chemoP↑, 17, chemoPv↑, 15, ChemoSideEff↓, 9, fatigue↓, 3, hepatoP↑, 6, IMPDH1↓, 1, IMPDH2↓, 1, Mucositis↓, 1, neuroP↓, 1, neuroP↑, 5, NP/CIPN↓, 2, OS↑, 12, PFS↑, 2, QoL↑, 4, radioP↑, 5, RenoP↑, 2, Risk↓, 6, Risk↑, 1, Sleep↑, 1, toxicity↓, 13, toxicity↝, 5, toxicity∅, 2, TumVol↓, 15, TumW↓, 12, Weight∅, 2,

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 1, GutMicro↑, 3, GutMicro↝, 1,
Total Targets: 942

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1, antiOx↑, 30, Catalase↓, 1, Catalase↑, 15, GPx↑, 12, GPx1↑, 1, GPx4↑, 1, GSH↑, 14, GSR↑, 1, GSTs↑, 5, H2O2↓, 1, HO-1↓, 2, HO-1↑, 9, Iron↓, 2, Keap1↓, 2, Keap1↑, 1, Keap1↝, 1, lipid-P↓, 7, MDA↓, 12, MDA↑, 1, MPO↓, 3, NOX4↓, 1, NRF2↑, 24, RNS↓, 1, ROS↓, 61, ROS↑, 1, mt-ROS?, 1, mt-ROS↑, 1, SOD↓, 1, SOD↑, 20, SOD1↑, 2, SOD2↑, 2, TAC↑, 2, TBARS↓, 2, VitC↑, 1, VitE↑, 1,

Metal & Cofactor Biology(tgid=2) ⓘ

Mitochondria & Bioenergetics(tgid=3) ⓘ

ADP:ATP↓, 1, compII↑, 1, compIII↑, 1, DRP1/DNM1L↓, 1, Insulin↑, 2, MFN2↑, 1, mtDam↓, 1, OXPHOS↑, 1, PDH↑, 1, PGC-1α↑, 3, PGC-1α↝, 1, SIRT3↑, 2,

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1, ALAT↓, 5, AMPK↑, 4, p‑AMPK↑, 1, ATP↑, 4, ECAR↓, 1, glucose↓, 4, GlucoseCon↑, 4, Glycolysis↓, 2, Glycolysis↑, 1, GSK‐3β↓, 1, GSK‐3β↑, 1, H2S↑, 1, HK1↑, 1, HK2↓, 2, lactateProd↓, 2, LDHA↑, 1, LDL↓, 2, lipidLev↓, 1, NADPH↑, 1, p‑PDK1 / PDPK1↓, 1, PDKs↓, 1, PFK↓, 1, PFK1↓, 1, PKM2↓, 4, PPP↓, 1, SIRT1↑, 6,

Cell Death(tgid=5) ⓘ

AIF↓, 1, Apoptosis↓, 3, BAX↓, 1, Casp↓, 1, Casp12↓, 1, Casp3↓, 4, Casp3↑, 1, Casp9↓, 1, Casp9↑, 1, Cyt‑c↓, 1, Fas↓, 1, Ferroptosis↓, 2, GranB/GZMB↓, 1, iNOS↓, 12, p38↓, 2, Pyro↓, 1, survivin↓, 1,

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 3, Akt↑, 4, p‑Akt↓, 1, ERK↓, 1, IGF-1R↓, 1, IκB?, 1, JAK↓, 1, JNK↓, 1, JNK↑, 1, p‑JNK↓, 2, MAPK↓, 3, mTOR↓, 2, mTOR↑, 1, p‑P70S6K↓, 1, PDGFR-BB↓, 1, PI3K↓, 6, PI3K↑, 3, PKCδ↓, 1, PKCδ↑, 1, PTEN↑, 1,

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1, ARNT↑, 1, ATF2↑, 1, ATF4↓, 2, FOXO1↑, 1, FOXO3↑, 2, HDAC↓, 1, other↓, 3, other↑, 6, other↝, 5,

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 2, CHOP/DDIT3↑, 1, p‑eIF2α↓, 1, cl‑eIF2α↑, 1, ER Stress↓, 4, GRP78/BiP↓, 1, GRP78/BiP↑, 1, HSP70/HSPA5↑, 1, HSPs↑, 1, PERK↓, 1, p‑PERK↑, 1, XBP-1↓, 1,

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↓, 1, Beclin-1/ATG6↑, 1, LC3‑Ⅱ/LC3‑Ⅰ↑, 1, LC3II↑, 1, p62↑, 1,

DNA Damage & Repair(tgid=10) ⓘ

ATM↑, 1, DNArepair↑, 1, P53↓, 1, PARP1↓, 1, PCNA↓, 1,

Cell Cycle & Senescence(tgid=11) ⓘ

E2Fs↑, 2, GADD45A↑, 1,

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD34↑, 1, FGF↑, 1, HH↓, 1, IGF-1↓, 1, IGFBP3↑, 1, Jun↑, 1, neuroG↑, 1,

Migration(tgid=13) ⓘ

AntiAg↑, 3, AP-1↓, 1, Ca+2↓, 2, EMT↓, 1, ITGB1↑, 1, MMP2↓, 1, MMP2↑, 1, MMP9↓, 1, MMP9↑, 1, NFAM1↑, 1, NFAT↑, 2, Rho↓, 1, TGF-β↓, 2, TGF-β↑, 1, TIMP1↓, 1, TIMP1↑, 1, TumCI∅, 1, TumCMig∅, 1, Vim↓, 1, α-SMA↓, 1, α-tubulin↓, 1,

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 2, angioG↑, 5, Hif1a↓, 19, Hif1a↑, 14, Hif1a↝, 1, Hif1a∅, 2, NO↓, 8, NO↑, 1, REL↑, 1, VCAM-1↓, 3, VEGF↓, 3, VEGF↑, 7, VEGFR2/KDR/Flk1↑, 1,

Barriers & Transport(tgid=15) ⓘ

BBB↑, 7, GLUT1↓, 1, GLUT3↑, 2, GLUT4↑, 3, H+/K+-ATPase↓, 1, IBI↑, 1, MMP↓, 1, MMP↑, 5, TRPC1↓, 1, TRPV1↑, 1,

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1, CD8+↑, 1, COX1↓, 1, COX2/PTGS2↓, 15, COX2/PTGS2↑, 1, CXCc↑, 1, CXCR2↑, 1, CXCR4↓, 1, ICAM-1↓, 1, IFN-γ↓, 1, IL10↓, 1, IL10↑, 2, IL17↓, 1, IL18↓, 2, IL1β↓, 5, IL2↑, 1, IL4↓, 1, IL6↓, 10, IL6↑, 1, IL8↓, 4, Imm↑, 3, Inflam↓, 46, LIF↑, 1, LPS↓, 1, pol-M2 MC↑, 1, MyD88↓, 1, NF-kB↓, 20, NF-kB↑, 1, NLRP3↓, 3, OSM↑, 1, PGE2↓, 4, TLR4↓, 3, TNF-α↓, 8,

Synaptic & Neurotransmission(tgid=18) ⓘ

5HT↑, 1, Ach↑, 1, AChE↓, 5, AChE↑, 1, BDNF↑, 2, ChAT↑, 1, NGF↑, 1, TrkB↑, 1,

Protein Aggregation(tgid=19) ⓘ

APP↓, 1, Aβ↓, 5, BACE/β-secretase↓, 2, tau↓, 3, p‑tau↓, 2, XO↓, 1,

Hormonal & Nuclear Receptors(tgid=20) ⓘ

ACE/ACE1↓, 1, ACE2↓, 1, AhR↑, 1, ARNT↑, 1, CYP19↓, 1, PPARα↑, 1, PPARα↝, 1, PPARγ↓, 1, PPARγ↑, 3,

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv?, 1, BioAv↓, 23, BioAv↑, 13, BioAv↝, 7, BioAv∅, 1, Dose⇅, 1, Dose↝, 7, Dose∅, 1, eff↓, 1, eff↑, 4, eff↝, 1, GSTA1↓, 1, GSTA1↑, 1, Half-Life↓, 1, Half-Life↝, 4, Half-Life∅, 4, P450↑, 1, selectivity↑, 1, Synergy↑, 2,

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 5, ALP↓, 1, AST↓, 7, BG↓, 1, BMD↑, 1, BP↓, 3, creat↓, 2, CRP↓, 1, IL6↓, 10, IL6↑, 1, IRes↝, 1, LDH↓, 4, Urea↓, 1,

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 5, antiAll↑, 5, AntiCan↓, 1, AntiCan↑, 5, AntiDiabetic↑, 8, antiPs↑, 3, AntiTum↑, 1, cardioP?, 1, cardioP↑, 16, cardioP⇅, 1, CardioT↓, 1, chemoP↑, 3, chemoPv↑, 2, cognitive↑, 9, diuretic↑, 1, hepatoP↓, 1, hepatoP↑, 18, memory↑, 11, motorD↓, 1, motorD↑, 3, neuroP↓, 1, neuroP↑, 34, Obesity↓, 7, Pain↓, 1, radioP↑, 1, RenoP↑, 7, Stroke↓, 5, toxicity↓, 19, toxicity↑, 2, toxicity↝, 4, toxicity∅, 6, Weight↓, 1, Wound Healing↑, 1,

Infection & Microbiome(tgid=24) ⓘ

AntiBio↑, 2, AntiViral↑, 2, Bacteria↓, 7, GutMicro↑, 7, Sepsis↓, 1,
Total Targets: 324

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a

14 Apigenin (mainly Parsley)
14 Baicalein
14 Resveratrol
14 Sulforaphane (mainly Broccoli)
12 Silymarin (Milk Thistle) silibinin
10 EGCG (Epigallocatechin Gallate)
9 Vitamin C (Ascorbic Acid)
9 Berberine
9 Metformin
8 Curcumin
8 Melatonin
8 Shikonin
7 Honokiol
6 Thymoquinone
6 Alpha-Lipoic-Acid
6 Chrysin
6 Quercetin
5 Silver-NanoParticles
5 Artemisinin
5 Radiotherapy/Radiation
5 Betulinic acid
5 Dichloroacetate
5 Magnetic Fields
5 Propolis -bee glue
5 Phenethyl isothiocyanate
4 Ashwagandha(Withaferin A)
4 Chlorogenic acid
4 Deguelin
4 Ellagic acid
4 Emodin
4 Graviola
4 Vitexin
4 Rosmarinic acid
4 Vitamin K2
3 Brucea javanica
3 brusatol
3 borneol
3 Boron
3 Capsaicin
3 chaetocin
3 Cinnamon
3 Citric Acid
3 Formononetin
3 Hydrogen Gas
3 HydroxyTyrosol
3 Isoliquiritigenin
3 Kaempferol
3 Licochalcone A
3 Licorice
3 Luteolin
3 Magnolol
3 MCT, metronomic chemo
3 methylseleninic acid
2 5-fluorouracil
2 Allicin (mainly Garlic)
2 Caffeic acid
2 Carvacrol
2 Celastrol
2 Electrical Pulses
2 Cisplatin
2 Fucoidan
2 Gambogic Acid
2 Isovitexin
2 Lutein
2 Lycopene
2 mebendazole
2 Modified Citrus Pectin
2 Oxygen, Hyperbaric
2 Proanthocyanidins
2 Piperlongumine
2 Sanguinarine
2 Wogonin
1 Coenzyme Q10
1 Annona atemoya Seed Extract
1 Auranofin
1 alpha Linolenic acid
1 Phyllanthus emblica/Emblica officinalis/Amla / Indian Gooseberry
1 Andrographis
1 Atorvastatin
1 tamoxifen
1 Baicalin
1 Biochanin A
1 Thymol-Thymus vulgaris
1 Sorafenib (brand name Nexavar)
1 Cannabidiol
1 Celecoxib
1 immunotherapy
1 Crocetin
1 Cucurbitacin
1 Bortezomib
1 Docosahexaenoic Acid
1 diet FMD Fasting Mimicking Diet
1 Diindolylmethane
1 Ormeloxifene (Centchroman)
1 Ferulic acid
1 Fenbendazole
1 Fisetin
1 Ai-Tong-An-Gao-Ji
1 flavonoids
1 Gallic acid
1 Garcinol
1 Genistein (soy isoflavone)
1 Geraniol
1 Ginkgolide B
1 γ-linolenic acid (Borage Oil)
1 HydroxyCitric Acid
1 Hops (Humulus lupulus)
1 phytic acid, Inositol hexakisphosphate
1 itraconazole
1 Ivermectin
1 Juglone
1 Lactobacillus
1 Paclitaxel/Taxol
1 Methylglyoxal
1 Methylsulfonylmethane
1 Mistletoe/Viscum album Extracts
1 Mushroom Lion’s Mane, Hericium erinaceus
1 Niclosamide (Niclocide)
1 Oroxylin-A
1 Oleuropein
1 doxorubicin
1 Rauwolfia serpentina/Indian Snakeroot
1 Rutin
1 salinomycin
1 Gemcitabine (Gemzar)
1 Salvia miltiorrhiza
1 Selenite (Sodium)
1 Aflavin-3,3′-digallate
1 Ursolic acid
1 Zinc

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:143  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Home Page